0.10Open0.10Pre Close0 Volume111 Open Interest2.50Strike Price0.00Turnover231.31%IV42.17%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier14DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type-0.0914Delta0.0857Gamma41.50Leverage Ratio-0.0107Theta-0.0002Rho-3.79Eff Leverage0.0014Vega
Zura Bio Stock Discussion
Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024
Zura Bio, a clinical-stage immunology company, announced its scheduled presentation at EULAR 2024 in Vienna from June 12-15. The company will unveil data on tibulizumab (ZB-106), a dual-pathway antibody targeting IL-17A and BAFF, focusing on its potential for treating Sjogren's syndrome and rheumatoid arthritis. The data aims to ...
Zura Bio (NASDAQ:ZURA), Piper Sandler, a prestigious investment firm, has initiated coverage on the biotechnology company, assigning it an "overweight" rating and setting an ambitious price target of $26. This optimistic forecast suggests a potential upside of 462.77% from the stock's previous close. The announcement by Piper Sandler und...
SC 13G: Statement of acquisition of beneficial ownership by individuals-RA Capital Management, L.P.(5.1%),Peter Kolchinsky(5.1%), etc.
NEWS
Zura Bio Raises $112.5M Through Private Placement Deal
NEWS
Zura Bio Announces Oversubscribed $112.5 Million Private Placement
No comment yet